The Alliance for Pharmacy Compounding Board of Directors has authorized the release of a public statement, “Understanding Law and Regulation Governing the Compounding of Peptide Products,” in light of the FDA’s 2023 addition of several peptides to Category 2 of its 503A Interim Bulks Guidance. The statement also describes the proper pathway for renominating substances for reconsideration by the agency. An updated APC Prescriber Brief on compounding of peptide products will also reportedly be made available later this week and will be posted with APC's other Prescriber Briefs.
NCPA
